In this article, we will discuss the 12 Best Monopoly Stocks to Buy According to Hedge Funds.
RBC Wealth Management noted that the consensus 2026 earnings growth forecast for the S&P 500 saw an increase from 13.6% at the start of the year to 23.3% by the end of June. Considering that it is the advanced stage of the economic cycle, this is an unusual leap over a short time span. Healthy economic data, along with little-to-no tangible signs of economic slowdown, aided stock prices.
The firm also reported that economists’ consensus forecast is for US GDP growth of 2.1% this year and next. This is roughly the level of the long-term average.
After a period of underperformance, the small-cap and mid-cap indexes advanced in H1, added RBC Wealth Management. The firm attributed the gains partly to strong performance by semiconductors and other stocks related to the AI data center buildout and improving consensus earnings growth estimates of small-cap companies, with 2027 projections surpassing the ones in the S&P 500. Also, the comparatively inexpensive valuations of the small-caps and mid-caps versus the large-cap indexes were rewarded by the market participants.
Amidst such trends, we will now have a look at the 12 Best Monopoly Stocks to Buy According to Hedge Funds.
Our Methodology
To list the 12 Best Monopoly Stocks to Buy According to Hedge Funds, we scanned through reputable research platforms and sifted through the holdings of The Monopoly ETF. We also mentioned the hedge fund sentiments around each stock, as of Q1 2026. Finally, the stocks are arranged in ascending order of their hedge fund sentiments.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
12 Best Monopoly Stocks to Buy According to Hedge Funds
12. Abbott Laboratories (NYSE:ABT)
Number of Hedge Fund Holders: 73
Abbott Laboratories (NYSE:ABT) is one of the Best Monopoly Stocks to Buy According to Hedge Funds. On June 30, Baird initiated coverage on the company’s stock with an “Outperform” rating, setting a price objective of $121.00. The firm sees Abbott Laboratories (NYSE:ABT)’s portfolio as delivering steady top-line and earnings growth over the upcoming several years. As per the firm, the company’s medical device segment is expected to see an above-peer growth trajectory.
The company’s diagnostics, nutrition, and established pharmaceutical offerings enhance Abbott Laboratories (NYSE:ABT)’s reach throughout the healthcare spectrum. As per the firm, there is a clearer path to upside in FY 2027 and FY 2028, with new products and indication opportunities layering in, and Exact Sciences integration and synergies contributing to the results.
In a different update, Evercore ISI analyst Vijay Kumar reduced the firm’s price objective on Abbott Laboratories (NYSE:ABT)’s stock to $112 from $120 and maintained an “Outperform” rating. The firm’s Q2 preview for MedTech, Life Sciences Tools, and Diagnostics demonstrates healthy procedure volumes as well as capex trends throughout the sector.
Abbott Laboratories (NYSE:ABT) is engaged in discovering, developing, manufacturing, and selling health care products.
